Update Sustains Osimertinib Activity Against CNS Mets in NSCLC
New results again demonstrated the benefit of frontline osimertinib in patients with EGFR-positive advanced non-small cell lung cancer and CNS metastases at baseline.
View ArticleDurvalumab Data Published in NEJM as FDA Weighs NSCLC Approval
The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non-small cell lung cancer whose disease has not progressed following...
View ArticleImmunotherapy to Have Emerging Role in Squamous Cell Lung Cancer
George R. Blumenschein, MD, discusses the current treatment landscape for patients with squamous cell lung cancer.
View ArticleJapanese Approval Sought for Frontline Osimertinib in NSCLC
A sNDA has been submitted to Japan’s Pharmaceuticals and Medical Devices Agency for the use of osimertinib (Tagrisso) as a frontline treatment for patients with inoperable or recurrent EGFR-positive...
View ArticleNivolumab Improves Survival in Pretreated Chinese NSCLC Patients
Nivolumab improved survival versus docetaxel in a predominantly Chinese population of patients with pretreated advanced or metastatic non-small cell lung cancer.
View ArticleOptimal Sequencing and Patient Selection Investigated in NSCLC
Frank E. Mott, MD, discusses optimal treatment selection strategies for patients with NSCLC.
View ArticleSimon Says Immunotherapy Combo Regimens on Horizon in NSCLC
George R. Simon, MD, discusses the advancements being made with immunotherapy for the treatment of NSCLC.
View ArticleExpert Discusses Developments in ALK/ROS1-Positive NSCLC
Vincent K. Lam, MD, discusses the treatment paradigm for patients with ALK/ROS1-translocated NSCLC.
View ArticleFDA Lifts Holds on 2 Nivolumab Myeloma Trials
The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma.
View ArticleFrontline Atezolizumab Regimen Improves PFS in NSCLC
Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced...
View ArticleAbemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer
The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.
View ArticleFDA Grants Priority Review to Pembrolizumab for Relapsed/Refractory PMBCL
The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for adult and pediatric patients with relapsed/refractory primary...
View ArticleAtezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or...
In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for...
View ArticlePembrolizumab Misses Endpoints in Phase III Gastric Cancer Trial
Pembrolizumab did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III...
View ArticleImmunotherapy Resistance Remains a Puzzle
Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies,...
View ArticleDeeper Understanding Emerging of KRAS Biology in NSCLC
Ferdinandos Skoulidis, MD, PhD, discusses potential treatment options for KRAS-mutated lung cancer and highlighted developments in biomarker research in other areas in the field.
View ArticleImmunotherapy Emerges in Stage III NSCLC Treatment Landscape
John Heinzerling, MD, discusses the impact of durvalumab and other developments in the treatment of patients with stage III non-small cell lung cancer.
View ArticleFDA Grants Frontline Osimertinib Priority Review for NSCLC
The FDA has granted a priority review to a supplemental new drug application for the use of osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR...
View ArticleFrontline Findings Put Fresh Focus on Immunotherapy in NSCLC
Findings from the phase III IMpower150 study have placed renewed focus on the optimal role for immunotherapy in the frontline setting for patients with advanced non
View ArticleFDA Approves Adjuvant Nivolumab for Melanoma
The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.
View Article
